<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129458">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01932476</url>
  </required_header>
  <id_info>
    <org_study_id>GC001</org_study_id>
    <nct_id>NCT01932476</nct_id>
  </id_info>
  <brief_title>Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes</brief_title>
  <official_title>Randomized Double-Masked Gluten Challenge to Evaluate Markers of Autoimmunity in Patients With Type-1 Diabetes and Celiac Disease After Oral Gluten Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ImmusanT, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the immune response causing celiac disease
      is related to the autoimmune response causing type-1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants meeting eligibility criteria will have blood collected before and after a
      three-day oral gluten challenge. This blood will be tested for biomarkers associated with
      islet autoimmunity and gluten-specific cellular immunity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Change in Markers of Autoimmunity</measure>
    <time_frame>Baseline and day 3 post challenge</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples for markers of autoimmunity will be taken before and day 3 post challenge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Symptoms</measure>
    <time_frame>Baseline and 6 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Gastrointestinal symptoms are recorded in a standardized diary at baseline and for 6 days inclusive of challenge.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Celiac Disease Alone Gluten Challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celiac Disease Alone Sham Challenge</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celiac Disease and T1D Gluten Challenge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Celiac Disease and T1D Sham Challenge</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gluten Challenge</intervention_name>
    <description>Three-day gluten containing dietary challenge.</description>
    <arm_group_label>Celiac Disease Alone Gluten Challenge</arm_group_label>
    <arm_group_label>Celiac Disease and T1D Gluten Challenge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sham Challenge</intervention_name>
    <description>Three-day sham (gluten free) dietary challenge</description>
    <arm_group_label>Celiac Disease Alone Sham Challenge</arm_group_label>
    <arm_group_label>Celiac Disease and T1D Sham Challenge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Celiac Disease by histology and serology

          -  For those with Type-1 Diabetes, at least one anti-islet antibody

          -  HLA-DQ2.5 genotype

        Exclusion Criteria:

          -  Not following a gluten free diet for at least 12 months

          -  Known gluten exposure within the prior 2 months

          -  Treatment with systemic immune modifying biological agents (adalimumab, etanercept,
             infliximab, certolizumab pegol) in prior 6 months

          -  Treatment with systemic immunomodulatory agents in prior 30 days

          -  Human immunodeficiency virus infection, untreated hepatitis B virus, or hepatitis C
             virus infection

          -  Nut allergy

          -  Hemoglobin level below normal range

          -  History of angina

          -  Pregnant or lactating

          -  Severe symptoms to gluten challenge in the past

          -  Elevation in transglutaminase-IgA or deamidated gliadin peptide IgA or IgG greater
             than or equal to 50% above upper limit of normal

          -  Uncontrolled complications of type-1 diabetes or celiac disease which pose a risk to
             participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Gaglia, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Szubowicz, MPH</last_name>
    <phone>617-309-4493</phone>
    <email>sarah.szubowicz@joslin.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Baidal, MD</last_name>
      <phone>888-813-8669</phone>
      <email>david.baidal@joslin.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Gaglia, MD, MMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>August 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Joslin Diabetes Center</investigator_affiliation>
    <investigator_full_name>Jason Gaglia</investigator_full_name>
    <investigator_title>Assistant Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Celiac Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
